CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 72 enrolled
Drug / intervention
TAK-792 30 mg +11 moredrug
Likely dose
TAK-792 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02448719
NCT02448719Phase 1Completed
CompareCT.gov

A Randomized, Single-Center, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of TAK-792 in Healthy Subjects

Takeda·interventional·Posted May 19, 2015·Updated Mar 19, 2019

In Brief

A Phase 1 clinical trial evaluating TAK-792 30 mg, TAK-792 30 mg placebo, and 10 other interventions for Healthy Male Adults Participants. Completed, enrolled 72 participants across 1 site.

Detailed Summary

The purpose of this study is to characterize the safety and tolerability profile of TAK-792 when administered as a single oral dose in healthy Japanese and Caucasian male participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Male Adults Participants
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 19, 2015
Enrollment StartMay 27, 2015
Primary CompletionJan 28, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.1 years ago

Interventions

TAK-792 30 mgdrug

TAK-792 30 mg was administered in the morning after a fast.

TAK-792 30 mg placebodrug

TAK-792 30 mg placebo was administered in the morning after a fast.

TAK-792 100 mgdrug

TAK-792 100 mg was administered in the morning after a fast.

TAK-792 100 mg placebodrug

TAK-792 100 mg placebo was administered in the morning after a fast.

TAK-792 250 mgdrug

TAK-792 250 mg was administered in the morning after a fast.

TAK-792 250 mg placebodrug

TAK-792 250 mg placebo was administered in the morning after a fast.

TAK-792 500 mgdrug

TAK-792 500 mg was administered in the morning after a fast or after breakfast.

TAK-792 500 mg placebodrug

TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.

TAK-792 750 mgdrug

TAK-792 750 mg was administered in the morning after a fast.

TAK-792 750 mg placebodrug

TAK-792 750 mg placebo was administered in the morning after a fast.

TAK-792 1250 mgdrug

TAK-792 1250 mg was administered in the morning after a fast.

TAK-792 1250 mg placebodrug

TAK-792 1250 mg placebo was administered in the morning after a fast.